Study drug for FGFR2-mutated bile duct cancer
Part of Cancer clinical trials.
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and willing to sign the study consent form
- Your bile duct cancer must be advanced and cannot be removed by surgery, or it has spread
- Your tumor must have an FGFR2 fusion/rearrangement or mutation
- You should have had at least one prior cancer treatment for advanced disease (or none only if you are in the specific no-prior-therapy group)
- Your cancer scans must show at least one measurable tumor spot, and you can do normal daily activities (ECOG 0–1)
- You should be able to take the study pills and expect at least 12 weeks of life
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of freezing the tumor (cryoablation), an experimental immunotherapy (SHR-1701), and a targeted therapy pill (famitinib) for people with advanced bile duct cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This study tests a combination of two medications—pemigatinib and durvalumab—for people with advanced bile duct or gallbladder cancer that has stopped responding to prior treatment and has a specific genetic change (FGFR2 fusion). The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Advanced Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.